The Department of Drug Administration clarified on Thursday that immunosuppressant medicines have not been banned from sale, distribution or use in Nepal, following confusion over a recent notice. The department said the restrictions concern only the new production and import of 47 brands that either failed to meet prescribed standards or did not submit required risk assessment documents within the given time. It said the supply of the medicines would continue smoothly.